Global Closed System Drug Transfer Devices Market - 2024 - 2031

Report Overview

The Global Closed System Drug Transfer Devices Market reached US$ 1.25 billion in 2023 and is expected to reach US$ 4.37 billion by 2031 growing with a CAGR of 14.8% during the forecast period 2024-2031.

A closed system drug transfer device (CSTD) is a specialized medical equipment designed to safely transfer hazardous drugs by preventing the introduction of external contaminants into the system and blocking the release of hazardous drug substances or vapors outside the system.

The primary purpose of CSTDs is to establish a secure environment that significantly reduces the risk of exposure to dangerous substances. Exposure to these hazardous drugs can have severe health consequences for healthcare professionals and patients, including skin irritation, reproductive issues, and even cancer. By creating a closed system, CSTDs play a crucial role in safeguarding the well-being of everyone involved in the handling of these potent medications.

CSTDs generally follow one of two design concepts: physical barrier CSTDs and air cleaning CSTDs. The physical barrier CSTD uses mechanical means to block the escape of drug vapors, aerosols, and liquids into the surrounding environment. They also prevent the intake of contaminants from the environment into the sterile drug pathway. The physical barrier prevents direct contact between the hazardous drug and the environment or healthcare worker. It creates an impenetrable boundary to contain the drug and maintain sterility.

Another one is the air cleaning CSTDs use filtration technology to remove drug contaminants from the airflow, preventing their release into the environment. They also filter incoming air to remove environmental contaminants before they can enter the sterile drug pathway.

Both physical barrier and air-cleaning CSTDs are designed to achieve the same goal of protecting healthcare workers and the environment from exposure to hazardous drugs while preserving the sterility of the drug pathway. The choice between the two depends on factors like drug properties, facility layout, and user preference. When used properly, CSTDs significantly reduce the risks associated with handling hazardous medications.

Market Dynamics: Drivers

Rising prevalence of cancer and technological advancements

The demand for the global closed system drug transfer devices (CSDTs) market is driven by multiple factors. One of the primary factors is the rising prevalence of cancer and technological advancements. The global incidence of cancer is increasing rapidly, leading to a demand for chemotherapy and other hazardous medications.

Utilizing closed system drug transfer devices (CSTDs) is essential for protecting healthcare workers from occupational exposure to hazardous drugs. These devices are specifically engineered to reduce the risks linked to handling powerful medications, especially chemotherapy drugs, which can present serious health threats if healthcare personnel are unintentionally exposed.

As per WHO data in February 2024, in 2022, approximately 20 million new cancer cases were reported globally, resulting in nearly 9.7 million deaths. The most prevalent types of cancer that year included lung cancer, with 2.5 million cases (12.4% of all cancers), breast cancer at 2.3 million cases (11.6%), and colorectal cancer with 1.9 million cases (9.6%).

Lung cancer was the leading cause of cancer-related deaths, accounting for about 1.8 million fatalities (18.7%), followed by colorectal cancer with 900,000 deaths (9.3%) and liver cancer with 760,000 deaths (7.8%). Projections indicate that by 2050, the number of cancer cases could rise to 35 million, primarily due to population growth. Consequently, the rise in cancer cases demands the fueling of the need for closed system drug transfer devices (CSTDs) to facilitate the safe handling of these powerful drugs.

Moreover, innovations in closed system drug transfer device (CSTD) technology, such as the introduction of needle-free systems and enhanced sealing mechanisms, significantly improve usability and safety, thereby driving their adoption in healthcare settings.

In addition, key players in the industry's technological advancements, awareness programs, and key developments are driving the market growth. For instance, in September 2022, during the Formulation UK 2021 event organized by Oxford Global, Heloise Audat, Drug Product Team Leader for Biologics Drug Product Development at Sanofi, presented an insightful overview of Sanofi's methods for evaluating closed system drug transfer devices (CSTDs). The first regulations on CSTDs came around 2004, intending to protect healthcare workers from the risk of systematic contact with hazardous drugs.

Similarly, BD introduced the Hazardous Drug Surface Contamination Monitoring Program is a comprehensive end-to-end solution designed to help healthcare facilities assess their current practices, develop an effective testing plan, and implement a sustainable monitoring program for hazardous drug surface contamination. This program aims to protect healthcare workers from potential exposure to hazardous drugs during preparation and administration.

Also, in March 2022, Simplivia Healthcare Ltd., a prominent global developer of medical devices, announced the upcoming release of Chemfort, a new closed system transfer device (CSTD). This device is designed specifically to enhance safety for healthcare professionals involved in the preparation and administration of hazardous drugs.

Restraints

Factors such as the high cost of implementation of CSTDs, regulatory challenges, and lack of awareness among individuals, are expected to hamper the market.

Market Segment Analysis

The global closed system drug transfer devices (CSDTs) market is segmented based on type, component, closing mechanism, technology, end-user, and region.

The needleless system segment accounted for approximately 74.3% of the global closed system drug transfer devices (CSDTs) market share

The needleless system segment is expected to hold the largest market share over the forecast period. Needleless systems are specifically designed to prevent needle stick injuries, a significant hazard for healthcare workers who handle hazardous drugs. These systems eliminate the need for traditional needles, thereby reducing the risk of accidental exposure to toxic substances.

Moreover, key players in the industry introducing innovative devices & launches help to drive this segment's growth in the market. For instance, ICU Medical, Inc. introduced the chemo-lock closed system transfer device (CSTD) utilizes a mechanically and microbiologically closed, needle-free design to prevent the escape of hazardous drug vapors and maintain the sterility of the drug during compounding and administration.

Similarly, Yukon Medical introduced the Arisure closed system transfer device (CSTD) is designed to protect healthcare workers from exposure to hazardous drug vapors during the compounding, transportation, and administration of chemotherapy and other hazardous medications. The Arisure CSTD utilizes a needle-free, luer lock connection system that is intuitive and easy to use. This eliminates the risk of needlestick injuries compared to traditional needle-based systems. The luer lock connections form a secure, airtight seal when connecting vials, syringes, and IV bags.

Also, in November 2023, BD (Becton, Dickinson and Company) launched a new needle-free blood draw technology called the PIVO Pro, designed to enhance patient care and support the company's vision of a "One-Stick Hospital Stay." This innovative device has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is the first to offer compatibility with integrated and long peripheral IV catheters, including the Nexiva Closed IV Catheter System with NearPort IV Access.

Market Geographical Analysis

North America accounted for approximately 45.2% of the global closed system drug transfer devices (CSDTs) market share

North America region is expected to hold the largest market share over the forecast period owing to the increasing number of cancer cases in North America is a significant driver for the closed system drug transfer devices (CSTDs) market. As more patients require chemotherapy and other hazardous drug treatments, the a demand for safe handling solutions like CSTDs.

As per the American Cancer Society, in 2022, it was estimated that there would be approximately 1.9 million new cancer cases diagnosed and around 609,360 cancer-related deaths in the United States. The significant burden of cancer demand for closed system drug transfer devices (CSDTs) market.

In this region, a major number of key player's presence, technological advancements, product launches & approvals, well-advanced healthcare infrastructure, and growing oncology drug approvals are driving this market growth.

For instance, in September 2023, EQUASHIELD, a leading provider of closed system transfer devices (CSTDs) and automated pharmacy compounding solutions, has been recognized as the most used device for hazardous drug preparation and administration for five consecutive years by Pharmacy Purchasing & Products magazine. This remarkable achievement underscores EQUASHIELD's dedication to enhancing safety and efficiency in healthcare settings.

Similarly, in December 2023, West Pharmaceutical Services, Inc. a global leader in innovative solutions for injectable drug administration systems, announced FDA 510(k) clearance and launch of its Vial2Bag Advanced 13mm admixture device.

Also, in December 2021, B. Braun Medical Inc. announced the launch of the OnGuard 2 Closed System Transfer Device (CSTD) in the United States, which represents an advancement over its predecessor, the original OnGuard model. This new device incorporates several enhancements aimed at improving usability and safety for healthcare professionals handling hazardous drugs.

Market Segmentation

By Type

Membrane-to-Membrane Systems

Needleless Systems

By Component

Vial Access Devices

Syringe Safety Devices

Bag Spikes

Male and Female Luer Components

By Closing Mechanism

Click-to-Lock Systems

Luer-Lock Systems

Push-to-Turn

Color-to-Color Systems

By Technology

Diaphragm-Based Devices

Air Filtration Devices

By End-User

Hospitals

Oncology Clinics and Centers

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

The rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the closed system drug transfer devices (CSDTs) market include BD, ICU Medical, Inc., EQUASHIELD, B. Braun Medical Inc., Yukon Medical, Simplivia, West Pharmaceutical Services, Inc., Baxter International Inc., JMS Co.Ltd., and Corning Incorporated among others.

Key Developments

In April 2023, EQUASHIELD, a leading provider of closed system transfer devices (CSTDs) for hazardous drugs, announced that its EQUASHIELD Syringe Unit has received FDA clearance for full-volume use. This means the system's closed Syringe Unit prevents intended and unintended syringe plunger detachment and can be used safely up to its maximal nominal volume when handling hazardous drugs.

Why Purchase the Report?

To visualize the global closed system drug transfer devices (CSDTs) market segmentation based on type, component, closing mechanism, technology, end-user, and region and understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the closed system drug transfer devices (CSDTs) market with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in excel consisting of key products of all the major players.

The global closed system drug transfer devices (CSDTs) market report would provide approximately 78 tables, 72 figures, and 184 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies